Search

Objective. To present the immediate results of the splenectomy and preferable variants of transfusion therapy performance in patients with malignant non-Hodgkin’s lymphoma (MNHL). Materials and methods. 109 splenectomies were performed in patients with MNHL at the Department of General and Hematological Surgery of the institute from 1987 to 2020. The surgery was conducted by upper middle laparotomy under general anesthesia with intubation and, in particular cases, under spinal anesthesia. Results and discussion. The indications for splenectomy in patients with MNHL were as follows: massive splenomegaly, abdominal syndrome, associated hemocytopenia, inefficacy of cytostatic therapy, absence of diagnosis. All patients underwent vaccination against capsular bacteria for prevention of post-splenectomy infection in 10-14 days prior to the surgery. In case of anemia, which has been observed in 55 % of patients, the RBC concentrate was applied. All the patients, who received corticosteroid hormones prior to splenectomy, were administered prednisolone and hydrocortisone in the amount of 3 mg/kg of body mass at similar doses in an hour before the surgery for prevention of adrenal insufficiency during the surgery. The patients, who did not receive those medications, were also intramuscularly administered prednisolone at a dose of 0.5 mg/kg of body mass in an hour before the surgery for the same aim. The patients with PLT value 80.0×109/L) underwent two courses of leukapheresis. The patients with concomitant regional portal hypertension and in case of manipulations close to the pancreatic tail were administered somatostatin drugs in the course of the splenectomy. The splenectomy proved to be effective in 100 (92 %) of patients with MNHL: the great tumor mass was removed, the abdominal syndrome and concomitant hemocytopenia were neutralized, the signs of hypersplenism ceased, the hemolysis ceased, the cytostatic therapy became less necessary or unnecessary, the final diagnosis was established. The most serious postsurgical complications were acute adrenal failure (n=3), postsurgical intra-abdominal hemorrhage (n=2), pancreonecrosis (n=6). The postsurgical lethality was 2.7 %. Conclusions. The splenectomy proved to be effective in 92 % of patients with MNHL. The infusion therapy is individual for each patient and may include transfusion surgeries if indicated. The main objective of the infusion therapy in patients with MNHL is prevention and elimination of intra- and postsurgical complications.

Objective. To substantiate the safety of the infusion drug Hecoton in the early postoperative period in patients after cardiac surgery. Materials and methods. The study involved 60 patients receiving infusions of 200 ml colloid-hyperosmolar solution Gecotone. The solution contains: hydroxyethyl starch 130/0.42 – 5 %, polyatomic alcohol xylitol – 5 %, sodium lactate – 1.5 % and electrolytes Na+, K+, Ca++, Mg++, Cl-. The total amount of sodium in the solution is 270 mmol/l, which is 2 times higher than its concentration in blood plasma. The amount of lactate is 133 mmol/l, which is 4 times higher than in isotonic polyelectrolyte solutions. The total osmolarity of the drug is 890 mOsm/l. Vital signs, hemodynamics, glucose, arterial blood gas and acid-base status was evaluated before, during and infusion of medication. Results and discussion. Gecoton infusions had no adverse effect on hemodynamic parameters. All changes were not statistically significant. The mean values of the patient’s body temperature were within the normal range. There was no case of temperature increase above 36.9 °C in all patients after administration of the drug. There was a slight, statistically unreliable increase in the mean glucose level (from 8.57±0.42 to 9.53±0.48 mmol/l), which was most likely due to response to the surgical stress. Dynamics of arterial blood gas and acid-base state shows that pH and PaCO2 practically did not change, decrease of PaO2 from 115.69±5.52 mm Hg to 110,79±4,83 mm Hg after the infusion of Gecotone, was statistically unreliable, the base excess showed little dynamics to increase (from -1.84±0.35 to -1.29±0.23 mmol/l) after administration of Gecotone. Conclusions. The use of the complex colloid-hyperosmolar infusion solution Gecotone in patients after cardiac surgery in the early postoperative period is safe.